Do You Zoster Vaccinate? (6.19.2026)
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Read Article
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of PMR, GCA, and TAK. There were 5 overarching principles and 12 https://t.co/kpykylEbsr
Dr. John Cush @RheumNow( View Tweet )
CAR-T Cell Therapies at EULAR 2026
EurekAlert!
In an oral abstract presentation on Wednesday 3rd June, Fredrik Albach presented results for mivocabtagene autoleucel – an autologous, fully human CD19-directed CAR-T cell therapy – from Phase 1 of the prospective, open-label COMPARE trial in six patients with anti-
Read Article
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
https://t.co/FrghBJdlXj https://t.co/CbHYDKbnK9
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
This update includes new pandemic era evidence, recombinant zoster vaccine data, and new perspectives on vaccination in patients taking novel immunosuppressants. Five overarching principles and 10 vaccine recommendations follow.
Read Article
Late-Breaking Studies at EULAR 2026
MedPage Today
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical
Read Article
US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Recommendations on PMR, GCA, and Takayasu Arteritis
On the final day of EULAR 2026, Mukhtyar et al (on behalf of a large international task force) presented the updated EULAR recommendations for management of polymyalgia rheumatica (PMR), giant cell arteritis (GCA), and Takayasu arteritis (TAK). There were 5 overarching principles and 12
Read Article
Kyoto U. cohort study of 55 relapsing polychondritis pts (503 Pt-yrs) Rx w/ TNFi, IL-6i or none -- Crude relapse rates were 46.9/100PYs NoBio, 22.4 TNFi, & 12.5 IL-6Ri. Adjusted relapses signif lower w/ TNFi (IRR 0.4) & IL-6Ri (IRR 0.2) vs no biologic. Estimates for hospitalised https://t.co/h6IcVWjqfp
Dr. John Cush @RheumNow( View Tweet )
A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8
Dr. John Cush @RheumNow( View Tweet )
“Science is organized knowledge. Wisdom is organized life.” - Immanuel Kant
Dr. John Cush @RheumNow( View Tweet )
Vasculitis Updates: Glucocorticoid use in AAV and GCA
Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb
Dr. John Cush @RheumNow( View Tweet )
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv
Dr. John Cush @RheumNow( View Tweet )
EULAR 2026 Rheumatology RoundUp
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
Read Article
PsA Topic Panel: EULAR 2026
Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071
https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB
Dr. John Cush @RheumNow( View Tweet )
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this
Read Article
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
Read Article
Exploring Idiopathic Myopathies
#EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
Dr. John Cush @RheumNow( View Tweet )
Hot topic: menopause and inflammatory arthritis outcomes in RA and PsA
Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.
Read Article
Digital Platforms and AI
Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf
Dr. John Cush @RheumNow( View Tweet )
Understanding Comorbidities in RMD
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush @RheumNow( View Tweet )
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.
Dr. John Cush @RheumNow( View Tweet )
Day 1 Report from EULAR 2026
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush @RheumNow( View Tweet )
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃
https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Recent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
EULAR 2026 Daily Podcast Day 3a-
EULAR 2026 Daily Podcast Day 2a
-
EULAR 2026 Daily Podcast Day 1a
